MannKind’s (MNKD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MannKind (NASDAQ:MNKD) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on MNKD. Leerink Partners initiated coverage on shares of MannKind in a research note on Thursday, November 13th. They set an “outperform” rating and a $7.00 price objective for the company. Wall Street Zen upgraded MannKind from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Zacks Research lowered MannKind from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. Finally, Truist Financial set a $9.00 price objective on MannKind in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.21.

MannKind Stock Performance

Shares of MNKD stock opened at $3.28 on Wednesday. The company has a market capitalization of $1.01 billion, a P/E ratio of 164.08 and a beta of 0.84. MannKind has a fifty-two week low of $2.93 and a fifty-two week high of $6.51. The stock has a 50 day moving average price of $5.55 and a two-hundred day moving average price of $5.35.

MannKind (NASDAQ:MNKD) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.The firm had revenue of $111.96 million during the quarter, compared to the consensus estimate of $99.85 million. During the same quarter in the prior year, the business posted $0.03 EPS. The firm’s revenue for the quarter was up 45.8% on a year-over-year basis. As a group, equities analysts predict that MannKind will post 0.1 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Michael Castagna sold 107,920 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total value of $601,114.40. Following the completion of the transaction, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at approximately $13,951,691.44. This represents a 4.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 262,846 shares of company stock worth $1,546,840 in the last quarter. Company insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its stake in shares of MannKind by 19.8% in the 1st quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 9,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in MannKind by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock worth $1,059,000 after purchasing an additional 6,079 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in MannKind by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock worth $3,374,000 after purchasing an additional 53,202 shares during the period. Sumitomo Mitsui Trust Group Inc. bought a new position in shares of MannKind during the second quarter valued at approximately $42,000. Finally, Teacher Retirement System of Texas lifted its holdings in shares of MannKind by 4.7% during the second quarter. Teacher Retirement System of Texas now owns 77,726 shares of the biopharmaceutical company’s stock valued at $291,000 after purchasing an additional 3,506 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.